Rotational Stability of Acrysof IQ Vivity Extended Vision Toric IOL and Refractive Visual Outcome. (NCT05119127) | Clinical Trial Compass
CompletedNot Applicable
Rotational Stability of Acrysof IQ Vivity Extended Vision Toric IOL and Refractive Visual Outcome.
United States35 participantsStarted 2020-09-30
Plain-language summary
The purpose of this research is to assess the rotational stability of the AcrySof IQ Vivity Extended Vision Toric IOL and Refractive Visual outcome.
Who can participate
Age range45 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Subjects undergoing cataract extraction with intraocular lens implantation.
* Age: 45 years and older.
* Willing and able to comply with scheduled visits and other study procedures.
* Subjects who require an IOL power in the range of +15.0 D to +25.0 D.
* Subjects with regular corneal astigmatism that can be treated with T3-T5.
* Have good ocular health, with no pathology that compromises visual acuity (Outside of residual refractive error and cataract)
* Potential postoperative visual acuity of 0.2 logMAR/ETDRS (20/32 Snellen) or better in both eyes.
Exclusion Criteria:
* Glaucoma.
* Clinically significant corneal dystrophy.
* Previous corneal refractive surgery (i.e LASIK, PRK, RK)
* Pupil abnormalities.
* Concurrent infectious/non-infectious uveitis.
* History of chronic intraocular inflammation.
* Visually significant macular disease.
* History of retinal detachment.